MCIM
VRTX icon

Meadow Creek Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Meadow Creek Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$24.5M Buy
144,874
+44,438
+44% +$7.86M 0.48% 54
2019
Q2 		$18.4M Sell
100,436
-8,806
-8% -$1.54M 0.37% 65
2019
Q1 		$20.1M Buy
109,242
+2,074
+2% +$383K 0.41% 60
2018
Q4 		$17.8M Sell
107,168
-4,488
-4% -$778K 0.41% 53
2018
Q3 		$21.5M Sell
111,656
-6,766
-6% -$1.2M 0.42% 54
2018
Q2 		$20.1M Sell
118,422
-1,054
-0.9% -$163K 0.42% 52
2018
Q1 		$19.5M Buy
119,476
+54,570
+84% +$8.91M 0.42% 51
2017
Q4 		$9.73M Sell
64,906
-1,802
-3% -$267K 0.21% 101
2017
Q3 		$10.1M Sell
66,708
-23,358
-26% -$3.52M 0.24% 87
2017
Q2 		$11.6M Sell
90,066
-3,740
-4% -$450K 0.28% 77
2017
Q1 		$10.3M Sell
93,806
-9,282
-9% -$817K 0.25% 82
2016
Q4 		$7.59M Buy
+103,088
New +$8.39M 0.2% 88

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Meadow Creek Investment Management's VRTX Position: Q3 2019 in Review

Meadow Creek Investment Management increased its Vertex Pharmaceuticals (VRTX) stake by 44% in Q3 2019, buying an estimated $7.86M and bringing the position to 144,874 shares worth $24.5M. The position accounts for 0.48% of the portfolio, ranked #54.

Meadow Creek Investment Management first reported a position in VRTX in Q4 2016 and has held it in 12 quarters since. 708 funds tracked by Wall St. Rank hold VRTX as of Q3 2019.

  • Meadow Creek Investment Management held 144,874 shares of Vertex Pharmaceuticals worth $24.5M as of Q3 2019.
  • Meadow Creek Investment Management bought 44,438 Vertex Pharmaceuticals shares in Q3 2019, an estimated $7.86M.
  • Vertex Pharmaceuticals made up 0.48% of Meadow Creek Investment Management's portfolio in Q3 2019, its #54 holding.
  • Meadow Creek Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2016 and has held it in 12 quarters since.
  • 708 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.